TY - JOUR
T1 - Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma
T2 - results from a large patient cohort
AU - Dénes, Judit
AU - Swords, Francesca
AU - Rattenberry, Eleanor
AU - Stals, Karen
AU - Owens, Martina
AU - Cranston, Treena
AU - Xekouki, Paraskevi
AU - Moran, Linda
AU - Kumar, Ajith
AU - Wassif, Christopher
AU - Fersht, Naomi
AU - Baldeweg, Stephanie E
AU - Morris, Damian
AU - Lightman, Stafford
AU - Agha, Amar
AU - Rees, Aled
AU - Grieve, Joan
AU - Powell, Michael
AU - Boguszewski, Cesar Luiz
AU - Dutta, Pinaki
AU - Thakker, Rajesh V
AU - Srirangalingam, Umasuthan
AU - Thompson, Chris J
AU - Druce, Maralyn
AU - Higham, Claire
AU - Davis, Julian
AU - Eeles, Rosalind
AU - Stevenson, Mark
AU - O'Sullivan, Brendan
AU - Taniere, Phillipe
AU - Skordilis, Kassiani
AU - Gabrovska, Plamena
AU - Barlier, Anne
AU - Webb, Susan M
AU - Aulinas, Anna
AU - Drake, William M
AU - Bevan, John S
AU - Preda, Cristina
AU - Dalantaeva, Nadezhda
AU - Ribeiro-Oliveira, Antônio
AU - Garcia, Isabel Tena
AU - Yordanova, Galina
AU - Iotova, Violeta
AU - Evanson, Jane
AU - Grossman, Ashley B
AU - Trouillas, Jacqueline
AU - Ellard, Sian
AU - Stratakis, Constantine A
AU - Maher, Eamonn R
AU - Roncaroli, Federico
AU - Korbonits, Márta
PY - 2015/3
Y1 - 2015/3
N2 - CONTEXT: Pituitary adenomas and pheochromocytomas/paragangliomas (pheo/PGL) can occur in the same patient or in the same family. Coexistence of the two diseases could be due to either a common pathogenic mechanism or a coincidence.OBJECTIVE: The objective of the investigation was to study the possible coexistence of pituitary adenoma and pheo/PGL.DESIGN: Thirty-nine cases of sporadic or familial pheo/PGL and pituitary adenomas were investigated. Known pheo/PGL genes (SDHA-D, SDHAF2, RET, VHL, TMEM127, MAX, FH) and pituitary adenoma genes (MEN1, AIP, CDKN1B) were sequenced using next generation or Sanger sequencing. Loss of heterozygosity study and pathological studies were performed on the available tumor samples.SETTING: The study was conducted at university hospitals.PATIENTS: Thirty-nine patients with sporadic of familial pituitary adenoma and pheo/PGL participated in the study.OUTCOME: Outcomes included genetic screening and clinical characteristics.RESULTS: Eleven germline mutations (five SDHB, one SDHC, one SDHD, two VHL, and two MEN1) and four variants of unknown significance (two SDHA, one SDHB, and one SDHAF2) were identified in the studied genes in our patient cohort. Tumor tissue analysis identified LOH at the SDHB locus in three pituitary adenomas and loss of heterozygosity at the MEN1 locus in two pheochromocytomas. All the pituitary adenomas of patients affected by SDHX alterations have a unique histological feature not previously described in this context.CONCLUSIONS: Mutations in the genes known to cause pheo/PGL can rarely be associated with pituitary adenomas, whereas mutation in a gene predisposing to pituitary adenomas (MEN1) can be associated with pheo/PGL. Our findings suggest that genetic testing should be considered in all patients or families with the constellation of pheo/PGL and a pituitary adenoma.
AB - CONTEXT: Pituitary adenomas and pheochromocytomas/paragangliomas (pheo/PGL) can occur in the same patient or in the same family. Coexistence of the two diseases could be due to either a common pathogenic mechanism or a coincidence.OBJECTIVE: The objective of the investigation was to study the possible coexistence of pituitary adenoma and pheo/PGL.DESIGN: Thirty-nine cases of sporadic or familial pheo/PGL and pituitary adenomas were investigated. Known pheo/PGL genes (SDHA-D, SDHAF2, RET, VHL, TMEM127, MAX, FH) and pituitary adenoma genes (MEN1, AIP, CDKN1B) were sequenced using next generation or Sanger sequencing. Loss of heterozygosity study and pathological studies were performed on the available tumor samples.SETTING: The study was conducted at university hospitals.PATIENTS: Thirty-nine patients with sporadic of familial pituitary adenoma and pheo/PGL participated in the study.OUTCOME: Outcomes included genetic screening and clinical characteristics.RESULTS: Eleven germline mutations (five SDHB, one SDHC, one SDHD, two VHL, and two MEN1) and four variants of unknown significance (two SDHA, one SDHB, and one SDHAF2) were identified in the studied genes in our patient cohort. Tumor tissue analysis identified LOH at the SDHB locus in three pituitary adenomas and loss of heterozygosity at the MEN1 locus in two pheochromocytomas. All the pituitary adenomas of patients affected by SDHX alterations have a unique histological feature not previously described in this context.CONCLUSIONS: Mutations in the genes known to cause pheo/PGL can rarely be associated with pituitary adenomas, whereas mutation in a gene predisposing to pituitary adenomas (MEN1) can be associated with pheo/PGL. Our findings suggest that genetic testing should be considered in all patients or families with the constellation of pheo/PGL and a pituitary adenoma.
KW - Adenoma/epidemiology
KW - Adrenal Gland Neoplasms/epidemiology
KW - Adult
KW - Cohort Studies
KW - Female
KW - Genetic Association Studies
KW - Genetic Heterogeneity
KW - Genetic Predisposition to Disease
KW - Genetic Testing
KW - Humans
KW - Male
KW - Middle Aged
KW - Paraganglioma/epidemiology
KW - Pheochromocytoma/epidemiology
KW - Pituitary Neoplasms/epidemiology
KW - Young Adult
U2 - 10.1210/jc.2014-3399
DO - 10.1210/jc.2014-3399
M3 - Article (Academic Journal)
C2 - 25494863
SN - 0021-972X
VL - 100
SP - E531-41
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 3
ER -